Publications by authors named "C Reisner"
Article Synopsis
- Ventilator-associated pneumonia from Pseudomonas aeruginosa in hospitalized patients leads to high mortality, prompting the testing of the bispecific monoclonal antibody MEDI3902 (gremubamab) to prevent this condition in patients who are colonized with the bacteria.
- The EVADE study (NCT02696902) was a double-blind, placebo-controlled trial that recruited mechanically ventilated adults colonized with Pseudomonas aeruginosa and randomized them to receive either MEDI3902 or a placebo, focusing on the incidence of pneumonia over 21 days post-treatment.
- Results showed no significant difference in the incidence of pneumonia between the MEDI3902 and placebo groups, with 22.4
Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and cumulative gene-environment interactions over a lifetime. The evolving understanding of COPD biology provides novel opportunities for prevention, early diagnosis, and intervention. To advance these concepts, we propose therapeutic trials in two major groups of subjects: "young" individuals with COPD and those with pre-COPD.
View Article and Find Full Text PDFObjective: To evaluate the efficacy and safety of three doses of glycopyrrolate metered dose inhaler (GP MDI) in patients with uncontrolled asthma despite treatment with inhaled corticosteroid/long-acting β-agonists (ICS/LABA) with or without tiotropium, to characterize the benefit of triple therapy.
Method: This phase II/III, double-blind study randomized patients to 24 weeks' treatment with twice-daily GP MDI 36 µg, 18 µg, 9 µg, or placebo MDI (all delivered Aerosphere inhalers), or once-daily open-label tiotropium 2.5 µg.
Background And Objectives: Co-suspension Delivery™ Technology has been developed for the administration of albuterol sulfate pressurised inhalation suspension via metered-dose inhaler (AS MDI, PT007). We assessed the efficacy and safety of AS MDI versus Proventil in order to determine the optimal dose of AS MDI to take to Phase III clinical trials.
Methods: ASPEN (NCT03371459) and ANTORA (NCT03364608) were Phase II, randomised, crossover, multicentre studies of AS MDI versus Proventil in patients with persistent asthma.
Purpose: In the Phase III, 24-week KRONOS study (NCT02497001), triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) reduced exacerbation rates versus glycopyrrolate/formoterol fumarate (GFF) MDI in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) and no requirement for a history of exacerbations. We report a post hoc analysis investigating whether the benefits observed were driven by patients with ≥1 exacerbation in the 12 months prior to the study.
Patients And Methods: Patients received BGF MDI 320/18/9.